



Negative and disorganized symptoms mediate the relationship between verbal learning and global functioning in adolescents with early-onset psychosis

Runar Elle Smelror^{1,2} · Bjørn Rishovd Rund^{3,4} · Vera Lonning^{1,2} · Kjetil Nordbø Jørgensen^{1,2} · Kirsten Wedervang-Resell^{1,5} · Ole A. Andreassen^{1,5} · Torill Ueland^{1,3,5} · Anne M. Myhre⁵ · Ingrid Agartz^{1,2,6}

Received: 11 January 2019 / Accepted: 23 January 2020 / Published online: 8 February 2020
© The Author(s) 2020

Abstract

Neurocognitive deficits are associated with impaired global functioning and psychotic symptoms. However, whether symptoms can mediate the relationship between neurocognition and global functioning in adolescent psychosis is unclear. Here, we investigated if symptoms assessed with the Positive And Negative Syndrome Scale (PANSS), mediated the relationship between neurocognitive performance and global functioning in adolescents with non-affective early-onset psychotic disorders (EOP). Sixty-one adolescent EOP patients (age 12–18 years) from 2 Norwegian clinical cohorts were included. Linear regression models were applied to investigate associations between neurocognitive domains from the MATRICS Consensus Cognitive Battery (MCCB) and global functioning. PANSS symptoms were analyzed using the Wallwork/Fortgang five-factor model. Using the INDIRECT macro for SPSS, mediation effects were tested using bootstrapping with 95% bias corrected confidence intervals. Verbal learning was positively associated with global functioning ($P < 0.001$) and negatively associated with the disorganized symptom factor ($P = 0.002$), controlling for age, sex and cohort. Testing of indirect effects, controlling for age, sex and cohort, showed that the Negative (point estimate = 1.56, 95% CI 0.22, 3.47) and Disorganized (point estimate = 1.24, 95% CI 0.05, 3.69) symptom factors significantly mediated the relationship between verbal learning and global functioning. We found that verbal learning, negative and disorganized symptoms influenced global functioning in adolescents with EOP, while reality-distorted positive symptoms did not. These results suggest that assessing these domains in EOP is helpful for planning treatment and rehabilitation programs focusing on functional outcome.

Keywords MATRICS · MCCB · Early-onset schizophrenia · Neurocognition

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00787-020-01479-7>) contains supplementary material, which is available to authorized users.

✉ Runar Elle Smelror
runar.smelror@medisin.uio.no

- ¹ NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- ² Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
- ³ Department of Psychology, University of Oslo, Oslo, Norway
- ⁴ Research Department, Vestre Viken Hospital Trust, Drammen, Norway
- ⁵ Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- ⁶ Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden

Introduction

Early-onset psychosis (EOP) includes psychotic disorders with age of onset before 18 years. Early-onset schizophrenia (EOS) is one of the leading causes of disease burden in adolescents between 15–19 years [1]. It is widely regarded as a neurodevelopmental disorder [2–7] with neurocognitive deficits as a core feature of the illness [8]. Neurocognitive deficits are present before the onset of illness [9–12], relatively stable over time [13–16] and found in children with familial high risk of schizophrenia [17]. Although the neurocognitive deficits in EOP are similar to adult schizophrenia patients [18, 19], the deficits in adolescents seem to be greater than in adults [8, 20, 21]. These findings suggest that abnormal neurodevelopment in schizophrenia is present early in life in a period of extensive brain maturation and before the onset of illness [22]. EOP is thus important to investigate as

adolescents are less influenced by any secondary effects of the disease, such as long-term medical treatment, unhealthy lifestyle, etc. Increased knowledge of cognitive functioning and neurodevelopment during this life period can provide new insight into the mechanisms contributing to impaired functional outcome and the development of psychosis [5, 6].

Long-term follow-up studies have showed that 42–74% of individuals with EOP had severely impaired functional outcome after 9–42 years (e.g. lived in a supervised home/institution, had symptoms most/all the time, had reduced/no work) [19, 23–28]. Few studies have investigated putative associations between neurocognition and functional outcome in EOP. Two studies, including patients with EOS, found that neurocognitive deficits in speed of processing, verbal learning, attention, working memory and executive functioning were associated with impaired functional outcome at follow-up [19, 29]. As neurocognition is not part of the diagnostic criteria of psychotic disorders, symptom reduction on clinical rating scales (e.g. the Positive and Negative Syndrome Scale (PANSS) [30]) is often used as the only indicator of treatment success in clinical trials of schizophrenia. While the original PANSS includes three subscales, factor analyses show that five-factor models show better statistical validity, with the Wallwork/Fortgang model [31] showing the most optimal statistical fit for adult first-episode psychosis patients [32]. This model includes Positive, Negative, Disorganized/concrete, Excited and Depressed symptom factors, and separates reality-distorted positive symptoms (e.g. delusions and hallucinations) from disorganized symptoms (e.g. conceptual disorganization and reduced attention). This is in line with factor analyses suggesting that disorganized symptoms represent a different construct than positive symptoms [33, 34]. This is important as negative and disorganized symptoms have been more strongly associated with neurocognitive deficits than positive symptoms [35]. Stronger associations have also been found between negative symptoms and impaired functional outcome in EOP [36] and adult schizophrenia [37, 38], compared to positive symptoms. A recent study of adult first-episode psychosis patients and a former meta-analysis found that negative symptoms partially mediated the relationship between neurocognitive performance and global functioning in adult patients, while no significant association was found for reality-distorted positive symptoms [39, 40]. Disorganized symptoms were not assessed in these studies.

To the best of our knowledge, no studies have investigated if characteristic symptoms of psychosis mediate the relationship between neurocognitive performance and global functioning in adolescents with EOP. This may shed light on the nature of this relationship and help identify which psychotic symptoms are relevant predictors of functioning in adolescent psychosis. The present study examined whether neurocognitive performance, assessed with the MCCB, was

associated with global functioning in EOP, and whether symptom domains from the Wallwork/Fortgang five-factor model mediated this relationship. Based on previous research in adolescent schizophrenia [19, 29], we hypothesized that speed of processing, verbal learning, attention, working memory and global cognition would be associated with global functioning in EOP. Furthermore, based on a previous systematic review [35] and research in adult schizophrenia [39, 40], we hypothesized that the Negative and Disorganized/concrete symptom factors would mediate this relationship, while no significant mediation effects would be found for positive symptoms.

Materials and methods

Participants

A total of 61 adolescents with early-onset non-affective psychotic disorders (EOP) were combined from 2 Norwegian clinical cohorts at the University of Oslo (the Thematically Organized Psychosis Study for Youth [Youth-TOP] and the Early-Onset Study). All participants were recruited from adolescent psychiatric inpatient units and outpatient clinics in the Oslo region from 2013–2016 (Youth-TOP) and 2005–2007 (Early-Onset Study). The Youth-TOP has an ongoing inclusion of participants and no neurocognitive patient data have previously been reported (see [41] for more information about patient characterization). Neurocognitive data from the Early-Onset Study have been published in previous papers, e.g. [15, 18, 42]. The inclusion criteria in both cohorts were: (1) Non-affective early-onset psychosis (schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, brief psychotic disorder), according to the *Diagnostic and Statistical Manual of Mental Disorders, fourth edition* (DSM-IV), (2) age between 12 and 18 years, (3) written informed consent obtained from participants, parents or guardians (if the participant was under 16 years), (4) language abilities to complete the interviews and self-rating questionnaires. The exclusion criteria in both cohorts were: (1) IQ below 70, (2) previous moderate/severe head injury, (3) a diagnosis of substance-induced psychosis, (4) organic brain disease. Demographic and clinical information of the participants are provided in Table 1.

Clinical measures

Diagnoses were confirmed using the Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version (K-SADS-PL) [43] in the Youth-TOP study and the Structural Clinical Instrument of Diagnosis for DSM-IV Axis I disorders (SCID-I), modules

Table 1 Demographic and clinical characteristics of the participants, and statistical tests for differences between the two cohorts

	Youth-TOP <i>N</i> = 34	Early-Onset Study <i>N</i> = 27	Test statistics
Inclusion years	2013–2016	2005–2007	
Diagnostic assessment	K-SADS-PL ^a	SCID-I ^b	
CGAS/GAF-F ^c (SD)	43.2 (10.3)	48.0 (15.2)	$t(44) = 1.41, P = 0.17$
Sex, female (%)	21 (62)	14 (52)	$\chi^2(1) = 0.61, P = 0.44$
Hand dominance, right (%)	31 (91)	23 (85)	$\chi^2(1) = 0.53, P = 0.47$
Mother's education, years (SD)	14.7 (2.7)	12.9 (2.8)	$t(56) = -2.51, P = 0.02$
Age, years (SD)	16.2 (1.3)	15.9 (1.8)	$t(59) = -0.13, P = 0.53$
IQ (SD)	100.4 (12.4)	95.2 (14.4)	$t(59) = -1.51, P = 0.14$
Ethnicity, caucasian (%)	30 (88)	21 (78)	$\chi^2(1) = 1.20, P = 0.27$
Diagnosis (%)			$\chi^2(4) = 3.75, P = 0.44$
Schizophrenia	21 (62)	12 (44)	
Schizoaffective disorder	1 (3)	3 (11)	
Schizophreniform disorder	0 (0)	1 (4)	
Brief psychotic disorder	1 (3)	1 (4)	
Psychosis not otherwise specified	11 (32)	10 (37)	
Daily nicotine use, yes (%)	9 (27)	6 (23)	$\chi^2(1) = 0.09, P = 0.76$
Alcohol use, yes (%)	12 (35)	17 (63)	$\chi^2(1) = 4.62, P = 0.03$
Cannabis use, yes (%)	8 (24)	4 (15)	$\chi^2(1) = 0.72, P = 0.40$
Antipsychotic med., yes, <i>n</i> (%)	18 (53)	19 (70)	$\chi^2(1) = 1.92, P = 0.17$
Aripiprazole	9 (50)	2 (11)	
Risperidone	3 (16)	2 (11)	
Quetiapine	4 (22)	6 (31)	
Olanzapine	1 (6)	6 (31)	
Ziprasidone	0 (0)	2 (11)	
Clozapine	1 (6)	1 (5)	
Age of onset, mean years (SD)	14.3 (1.9)	14.1 (2.0)	$t(59) = -0.41, P = 0.68$
DUP ^d , weeks (SD)	38.5 (47.6)	35.0 (51.5)	$t(59) = 0.28, P = 0.78$
PANSS ^e (SD)			
Positive	17.3 (4.1)	14.9 (4.2)	$t(59) = -2.26, P = 0.03$
Negative	19.2 (8.0)	12.2 (5.3)	$t(57) = -4.10, P < 0.001$
General	36.5 (8.1)	29.7 (7.4)	$t(59) = -3.37, P = 0.001$
PANSS Wallwork/Fortgang (SD)			
Positive	2.9 (0.89)	2.5 (0.83)	$t(59) = -1.99, P = 0.05$
Negative	2.8 (1.18)	1.9 (0.76)	$t(57) = -3.45, P = 0.001$
Disorganized/concrete	2.2 (0.94)	1.6 (0.64)	$t(58) = -3.02, P = 0.004$
Excited	1.7 (0.55)	1.7 (0.63)	$t(59) = -0.04, P = 0.97$
Depressed	2.8 (0.88)	2.6 (1.13)	$t(49) = -0.87, P = 0.39$

^aSchedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version (K-SADS-PL [43])

^bStructured Clinical Instrument of Diagnosis for DSM-IV Axis I Disorders, modules A-D (First et al. [44])

^cChildren's Global Assessment Scale (CGAS) [45]. Global Assessment of Functioning (GAF) Scale (split DSM-IV version) [46]

^dDuration of untreated psychosis

^ePositive And Negative Syndrome Scale [30]

Bold values indicate $P \leq 0.05$

A-D [44], in the Early-Onset Study. For both cohorts, current psychopathology was assessed using the PANSS [30], and analyzed using the Wallwork/Fortgang five-factor model,

consisting of Positive, Negative, Disorganized/concrete, Excited, and Depressed symptom factors [31]. Although the Wallwork/Fortgang model has not been validated in

adolescents, it has shown the most optimal fit for adult first-episode schizophrenia patients, aged 18–65 years [32].

The interviewers in both studies were clinical psychologists or medical doctors who had completed an inter-rater reliability training course ($\geq 80\%$ inter-rater reliability) in PANSS assessment based on a training program developed at the University of California, Los Angeles. All interviewers participated in regular diagnostic consensus meetings led by a senior clinical researcher in the field of psychosis.

Global functioning

The participants' level of global functioning was assessed using the Children's Global Assessment Scale (CGAS) [45] in the Youth-TOP study and the Global Assessment of Functioning Scale, split DSM-IV version (GAF-F) [46, 47], in the Early-Onset Study. Both rating scales are based on the Global Assessment Scale [48], so the scoring of functioning is similar, ranging from 0 (lowest) to 100 (highest). The scales include behavior and activities indicative of daily functioning, such as social functioning, school performance and independent living [39, 49]. Despite minor differences in the naming of anchor points (e.g. scores from 51–60 are defined as “variable functioning” in the CGAS and “moderate functioning” in the GAF-F), the descriptions of functioning within each anchor point is similar between the scales (see [50] for more information about the scales). Although the anchor points in the CGAS contain both functioning and symptoms, while the GAF-F only contains functioning, we considered the two scales to be adequately comparable to allow us to merge for analysis of global functioning in the combined cohort. No significant differences were found between the CGAS and the GAF-F scores between the two cohorts (Table 1).

Neurocognitive measures

The participants underwent intelligence assessment using the Wechsler Abbreviated Scale of Intelligence [51]. Neurocognitive profiling was performed using a licensed translated version of the MATRICS Consensus Cognitive Battery (MCCB) [52], with the exception of the social cognition test Mayer–Salovey–Caruso Emotional Intelligence Test (MSCEIT) [53]. The MCCB was developed for clinical trials of schizophrenia [54] and has been successfully used to assess cognitive functioning in children [55] and adolescents [18, 56]. The nine included tests covered six neurocognitive domains: (1) *Speed of processing*, measured with the BACS Symbol coding [57], Trail making test, part A (TMT-A) [58], and Category fluency: Animal naming [59], (2) *Attention/vigilance*, measured with the Continuous performance test, identical pairs (CPT-IP) [60], (3) *Working memory*, measured with the WMS-III Spatial span [61] and

Letter-number span [62], (4) *Verbal learning*, measured with the Hopkins verbal learning test, revised (HVLTR) [63], (5) *Visual learning*, measured with the Brief visuospatial memory test, revised (BVMTR) [64], and (6) *Reasoning and problem solving*, measured with the NAB Mazes [65]. The HVLTR test was originally validated for age ≥ 16 years but has been successfully used and standardized in children and adolescents [56, 66–68].

Statistical analyses

Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 25. All tests were two-tailed. Independent-sample *t* tests were used for analyses of cohort comparisons of continuous variables and chi-square (χ^2) tests for comparisons of categorical data. We transformed the neurocognitive raw test scores from the MCCB in the total sample to standard scores (*z* scores) using the SPSS standardization function. High scores on the TMT-A test indicate impairment and were reversed. In domains containing more than one subtest and for the global cognition score, composite scores were calculated by summing the standard scores of relevant tests and transforming the sum scores to standard scores using the same procedure as described above. This procedure is in line with previous MCCB standardization studies [56, 69]. In the main analysis examining associations between neurocognition and global functioning, we applied separate linear regression models using the neurocognitive domains and global cognition as predictor variables and global functioning as the outcome variable. IQ was not included as it has been found to be moderately to highly correlated with the MCCB domains and the global cognition score [70, 71]. Age, sex and cohort were added as covariates as age and sex effects have been found in adolescent performance on the MCCB [56] and to avoid potential systematic cohort differences. Correction for multiple testing was performed using Bonferroni, in which $P \leq 0.007$ was considered significant in the main analysis ($P = 0.05/7$ neurocognitive domains). Based on the results from the main analysis, we examined associations between (1) neurocognition and symptoms, using the mean symptom factor scores as predictor variables and the relevant neurocognitive domains as outcome variables, controlling for age, sex and cohort; and (2) symptoms and global functioning, using the symptom factors as predictor variables and global functioning as the outcome variable, controlling for age, sex and cohort. In both secondary analyses, $P \leq 0.01$ was considered significant ($P = 0.05/5$ symptom factors). Lastly, to examine if symptoms mediated the relationship between the relevant neurocognitive domains and global functioning, we applied separate mediation analyses of the five symptom factors, controlling for age, sex and cohort, using the INDIRECT macro for SPSS [72]. The indirect effects were tested

using 95% bias corrected (BC) bootstrap intervals with 5000 bootstrap samples. The indirect effects were considered statistically significant if the confidence interval of each point estimate did not include zero (null value). Bootstrapping was preferred over the product-of-coefficients approach (i.e. the Sobel test), because no assumptions of normal distributions are required [73] and because this approach is considered to be more valid for testing of indirect effects [74].

Results

Patient characteristics

Demographic and clinical characteristics of the two cohorts are provided in Table 1. The participants in the Youth-TOP study had significantly higher PANSS scores (Positive: $t(59) = -2.26, P = 0.03$; Negative: $t(57) = -4.10, P < 0.001$; General: $t(59) = -3.37, P = 0.001$) and significantly higher scores on the Wallwork/Fortgang Positive [$t(59) = -1.99, P = 0.05$], Negative [$t(57) = -3.45, P = 0.001$] and Disorganized/concrete [$t(58) = -3.02, P = 0.004$] symptom factors, compared to the participants in the Early-Onset Study. Furthermore, the participants in the Youth-TOP study had mothers with significantly more years of education than the participants in the Early-Onset Study [$t(56) = -2.51, P = 0.02$], while a significantly higher proportion of participants in the Early-Onset Study had used alcohol compared to the participants in the Youth-TOP study [$\chi^2(1) = 4.62, P = 0.03$]. When comparing neurocognitive performance between the two cohorts, the participants in the Youth-TOP study had significantly higher scores on the Spatial span test [$t(58) = -2.59, P = 0.01$], Working memory domain [$t(58) = -2.55, P = 0.01$] and on the Global cognition score [$t(50) = -2.73, P = 0.01$] compared to the patients in the

Early-Onset Study. MCCB test and domain scores are presented in Table 2.

Associations between neurocognitive performance, global functioning, and symptoms

Verbal learning was the only neurocognitive domain significantly associated with global functioning, controlling for age, sex and cohort ($\beta = 0.50, P < 0.001, R^2 \text{ change} = 0.20$, model statistics (MS): $F(4, 55) = 5.92, P < 0.001, R^2 = 0.30$, Fig. 1a), and thus the only domain included in the subsequent analyses. For the other domains and the global cognition score, no significant associations were found (Speed of processing: $\beta = 0.22, P = 0.10, R^2 \text{ change} = 0.05$, MS: $F(4, 54) = 2.35, P = 0.07, R^2 = 0.15$; attention/vigilance: $\beta = -0.02, P = 0.87, R^2 \text{ change} = 0.00$, MS: $F(4, 51) = 1.04, P = 0.40, R^2 = 0.08$; working memory: $\beta = 0.01, P = 0.93, R^2 \text{ change} = 0.00$, MS: $F(4, 55) = 1.70, P = 0.16, R^2 = 0.11$; visual learning: $\beta = 0.13, P = 0.31, R^2 \text{ change} = 0.02$, MS: $F(4, 56) = 1.89, P = 0.12, R^2 = 0.12$; reasoning and problem solving: $\beta = 0.09, P = 0.52, R^2 \text{ change} = 0.01$, MS: $F(4, 56) = 1.71, P = 0.16, R^2 = 0.11$; global cognition: $\beta = 0.18, P = 0.25, R^2 \text{ change} = 0.03$, MS: $F(4, 47) = 1.42, P = 0.24, R^2 = 0.11$). When performing separate analyses of the two cohorts, verbal learning was the only neurocognitive domain significantly associated with global functioning in the Early-Onset Study after correcting for multiple testing. None of the associations between the neurocognitive domains and global functioning reached statistical significance in the Youth-TOP. The separate results for the two cohorts are presented in the supplemental material.

When investigating associations between the verbal learning domain and symptoms, controlling for age, sex and cohort, verbal learning was significantly negatively associated with the disorganized/concrete ($\beta = -0.40, P = 0.002$,

Table 2 MCCB test and domain scores of the participants, and statistical tests for differences between the two cohorts

MCCB test and domain scores	Youth-TOP N=34	Early-Onset Study N=27	Test statistics
Speed of processing, Z score	0.15 (0.98)	- 0.19 (1.01)	$t(57) = -1.30, P = 0.20$
BACS symbol coding	49.61 (12.98)	46.59 (11.26)	$t(58) = -0.95, P = 0.35$
Animal naming	21.09 (5.44)	18.35 (5.46)	$t(58) = -1.93, P = 0.06$
Trail making test A	36.22 (12.74)	35.92 (14.61)	$t(58) = -0.08, P = 0.93$
Attention/vigilance: CPT-IP d'	1.77 (0.68)	1.70 (0.70)	$t(54) = -0.38, P = 0.71$
Working memory, Z score	0.28 (0.96)	- 0.36 (0.95)	$t(58) = -2.55, P = 0.01$
WMS-III spatial span	16.62 (2.67)	14.81 (2.70)	$t(58) = -2.59, P = 0.01$
Letter-number span	12.94 (3.14)	11.70 (2.32)	$t(59) = -1.71, P = 0.09$
Verbal learning: HVLT-R	25.52 (5.19)	22.81 (5.50)	$t(58) = -1.95, P = 0.06$
Visual learning: BVMT-R	25.38 (6.79)	22.93 (8.78)	$t(48) = -1.20, P = 0.24$
Reasoning and problem-solving: NAB Mazes	20.29 (4.45)	17.85 (5.69)	$t(59) = -1.88, P = 0.07$
Global cognition, Z score	- 0.34 (0.90)	- 0.37 (0.98)	$t(50) = -2.73, P = 0.01$

Bold values indicate $P \leq 0.05$




Fig. 1 **a** The effect of verbal learning (X) on global functioning (Y), controlling for age, sex and cohort (cov). **b, c** Mediation models illustrating that negative and disorganized symptom factors (M) significantly mediate the relationship between verbal learning (X) and

global functioning (Y), controlling for age, sex and cohort (cov). For more information about the theory and path definitions, see [72]. MS model statistics

$R^2 \text{ change} = 0.13$, MS: $F(4, 55) = 6.49, P < 0.001, R^2 = 0.32$) symptom factor ($P \leq 0.01$ considered significant after Bonferroni correction). No significant associations were found for the other symptom factors after correcting for multiple testing (positive: $\beta = -0.08, P = 0.52, R^2 \text{ change} = 0.01$, MS: $F(4, 55) = 3.32, P = 0.02, R^2 = 0.19$; negative: $\beta = -0.32, P = 0.02, R^2 \text{ change} = 0.08$, MS: $F(4, 55) = 4.97, P = 0.002, R^2 = 0.27$; excited: $\beta = -0.11, P = 0.36, R^2 \text{ change} = 0.01$, MS: $F(4, 55) = 3.45, P = 0.01, R^2 = 0.20$; depressed: $\beta = 0.06, P = 0.61, R^2 \text{ change} = 0.00$, MS: $F(4, 55) = 3.27, P = 0.02, R^2 = 0.19$).

When investigating associations between symptom factors and global functioning, controlling for age, sex and cohort, significant associations were found for the Negative ($\beta = -0.52, P < 0.001, R^2 \text{ change} = 0.20$, MS: $F(4, 56) = 6.13, P < 0.001, R^2 = 0.30$) and disorganized/

concrete ($\beta = -0.39, P = 0.004, R^2 \text{ change} = 0.13$, MS: $F(4, 56) = 4.14, P = 0.005, R^2 = 0.23$) symptom factors ($P \leq 0.01$ considered significant after Bonferroni correction). The other symptom factors did not reach statistical significance after correcting for multiple testing (Positive: $\beta = -0.20, P = 0.13, R^2 \text{ change} = 0.04$, MS: $F(4, 56) = 2.27, P = 0.07, R^2 = 0.14$; Excited: $\beta = -0.26, P = 0.04, R^2 \text{ change} = 0.07$, MS: $F(4, 56) = 2.83, P = 0.03, R^2 \text{ change} = 0.17$; depressed: $\beta = -0.21, P = 0.12, R^2 \text{ change} = 0.04$, MS: $F(4, 56) = 2.30, P = 0.07, R^2 \text{ change} = 0.14$).

Symptoms as mediators of the association between neurocognitive performance and global functioning

Verbal learning was the only neurocognitive domain significantly associated with global functioning and thus the only domain included in the mediation analyses for testing the indirect effects. The Negative (point estimate = 1.56, BC 95% CI 0.22, 3.47) and the Disorganized/concrete (point estimate = 1.24, BC 95% CI 0.05, 3.69) symptom factors significantly mediated the relationship (CI not including the null value) between verbal learning and global functioning, controlling for age, sex and cohort (i.e. testing the indirect effect of X on Y , through M , shown in Fig. 1b, c). For the other symptom factors, the indirect effects did not reach statistical significance (Positive: point estimate = 0.19, BC 95% CI - 0.33, 1.59; excited: point estimate = 0.34, BC 95% CI - 0.25, 1.81; depressed: point estimate = - 0.17, BC 95% CI - 1.54, 0.65). When performing separate mediation analyses of the two cohorts, the Excited symptom factor was the only factor significantly mediating the relationship between verbal learning and global functioning in the Early-Onset Study. None of the symptom factors significantly mediated the relationship between verbal learning and global functioning in the Youth-TOP. The separate results for the two cohorts are presented in the supplemental material.

Discussion

The purpose of this study was to examine associations between neurocognitive performance and global functioning, and to test whether symptoms mediated this relationship in adolescents with EOP. The main finding was that verbal learning was positively associated with global functioning, explaining 20% of the variance in the level of functioning, and that this association was significantly mediated by negative and disorganized symptoms. Our finding showing a significant association between verbal learning and global functioning is in accordance with two previous studies of patients with EOS [19, 29]. Our results are also in accordance with two previous studies including adult schizophrenia patients, showing that negative symptoms mediated the relationship between neurocognitive performance and global functioning, while positive symptoms did not [39, 40]. To the best of our knowledge, our study is the first to show that disorganized symptoms, as a separate construct from other positive symptoms, mediated the relationship between verbal learning and global functioning.

Verbal learning deficits are associated with earlier age of onset of psychosis [75] and transition to psychosis in high-risk individuals [76]. Deficits in this domain might be a predictor of, or contributing factor to, the clinical manifestation

of negative and disorganized symptoms, which are considered to be a core feature of schizophrenia [77–79]. It has been suggested that the clinical heterogeneity in schizophrenia is a representation of different underlying mechanisms categorized by a positive and negative syndrome. The positive syndrome includes mainly positive symptoms (hallucinations and delusions) and better functional outcome, while the negative syndrome includes mainly negative and disorganized symptoms, cognitive deficits, and poorer functional outcome [35, 78–80]. Thus, the patients in our sample with verbal learning deficits, negative and disorganized symptoms could represent a negative subgroup with poorer global functioning [35, 78–80] and a more general language deficit, possibly due to a dysfunction in the language-processing networks [81].

Contrary to our hypothesis, we did not find significant associations between global functioning and other neurocognitive domains or global cognition, which have been found in previous studies of EOS and in adult schizophrenia [19, 29, 49, 82]. One reason for the different results between our study and the two previous studies of adolescents [19, 29] may be that in the two previous studies, functional outcome was measured only at follow-up and compared with baseline neurocognitive functioning, while we only applied baseline data. Comparing our results to previous studies of adult patients [49, 82], the divergence in findings in our study might be due to different factors influencing neurocognitive functioning in adolescence as compared to in adulthood. For example, more supportive factors in the adolescents' rearing environment could help them to maintain their level of functioning. Moreover, different measures of neurocognition and functional outcome were applied in our study and the previous studies. However, our analyses showed that verbal learning and global functioning were more strongly associated with negative and disorganized symptoms than other symptoms. These findings are in accordance with a previous study showing that negative and disorganized symptoms showed stronger associations with neurocognitive deficits, than positive symptoms [35]. Moreover, negative symptoms have also been more strongly associated with impaired functional outcome in EOP [36] and adult schizophrenia [37, 38], compared to positive symptoms.

Strengths and limitations

The main strength of this study is the large and well-characterized cohort of adolescent EOP patients. However, the study has several limitations. First, the study was naturalistic and cross-sectional, and no empirical assumptions of causality could be made, only investigations of statistical associations. We assume that baseline deficits in verbal learning and the presence of negative and disorganized symptoms will affect long-term global functioning in adolescents with EOP,

but this must be investigated in a follow-up study. Second, global functioning was assessed using two different scales. Although the scales were considered to be sufficiently similar to merge and we controlled for cohort effects in the analyses, we cannot be certain that this did not bias the ratings of global functioning since no estimate of agreement between the two scales have been provided. Moreover, the ratings of functioning were based on the subjective impression of the interviewer. The interviewers were trained in scoring of CGAS and GAF, but no inter-rater reliability testing or observation of actual functioning was completed. Third, when performing separate analyses of the two cohorts, we found cohort differences in the regression and mediation analyses. Although cohort was added as a covariate in all the analyses, we cannot rule out that cohort differences may have biased the results. Fourth, it is unknown if medication effects have contributed to our findings as the combined cohort included medicated and unmedicated participants. Lastly, patient motivation was not assessed, although it has been shown to be related to cognitive performance in adult schizophrenia patients [83].

Conclusion

Our results confirm that verbal learning is an important neurocognitive domain for global functioning and that negative and disorganized symptoms mediate this relationship, while reality-distorted positive symptoms do not. Hence, our results support the notion that disorganized symptoms should be considered as an independent construct separate from other positive symptoms [33, 34]. Clinical implications of the study are that assessments of adolescents with EOP should include measures of verbal learning, negative and disorganized symptoms. This could be of value for cognitive remediation programs and in planning of psychosocial and psychopharmacological interventions aiming to improve global functioning.

Acknowledgements Open Access funding provided by Oslo University & Oslo University Hospital. We would like to thank all the participants for their contribution to this study. We would also like to thank Thorny Olafsdottir for her help with data collection.

Funding This work was supported by the South-Eastern Norway Regional Health Authority (2016-118 and 2017-097) and the Research Council of Norway (223273, 213700, and 250358).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The Youth-TOP and the Early-Onset Study were approved by the South-East Regional Committee for Medical and

Health Research Ethics and conducted in accordance with the Helsinki Declaration. Written informed consent was obtained from participants, parents or guardians (if the participant was under 16 years), prior to their inclusion in the studies.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Gore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C, Sawyer SM, Mathers CD (2011) Global burden of disease in young people aged 10–24 years: a systematic analysis. *Lancet* 377(9783):2093–2102. [https://doi.org/10.1016/S0140-6736\(11\)60512-6](https://doi.org/10.1016/S0140-6736(11)60512-6)
- Murray RM, Lewis SW (1987) Is schizophrenia a neurodevelopmental disorder? *Br Med J (Clinical research ed)* 295(6600):681
- Rapoport JL, Addington AM, Frangou S, Psych M (2005) The neurodevelopmental model of schizophrenia: update 2005. *Mol Psychiatry* 10(5):434
- Owen MJ, O'donovan MC, Thapar A, Craddock N (2011) Neurodevelopmental hypothesis of schizophrenia. *Br J Psychiatry* 198(3):173–175
- Insel TR (2010) Rethinking schizophrenia. *Nature* 468(7321):187
- Rapoport J, Giedd J, Gogtay N (2012) Neurodevelopmental model of schizophrenia: update 2012. *Mol Psychiatry* 17(12):1228
- Rund BR (2009) Is schizophrenia a neurodegenerative disorder? *Nord J Psychiatry* 63(3):196–201
- Nieto RG, Castellanos FX (2011) A meta-analysis of neuropsychological functioning in patients with early onset schizophrenia and pediatric bipolar disorder. *J Clin Child Adolesc Psychol* 40(2):266–280
- Trotta A, Murray R, MacCabe J (2015) Do premorbid and post-onset cognitive functioning differ between schizophrenia and bipolar disorder? A systematic review and meta-analysis. *Psychol Med* 45(2):381–394
- Woodberry KA, Giuliano AJ, Seidman LJ (2008) Premorbid IQ in schizophrenia: a meta-analytic review. *Am J Psychiatry* 165(5):579–587. <https://doi.org/10.1176/appi.ajp.2008.07081242>
- Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho B-C, Andreasen NC (2002) Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. *Am J Psychiatry* 159(7):1183–1189. <https://doi.org/10.1176/appi.ajp.159.7.1183>
- Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, Poulton R, Moffitt TE (2010) Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. *Am J Psychiatry* 167(2):160–169
- Frangou S, Hadjulis M, Vourdas A (2008) The Maudsley early onset schizophrenia study: cognitive function over a 4-year follow-up period. *Schizophr Bull* 34(1):52–59. <https://doi.org/10.1093/schbul/sbm124>

14. Jepsen JRM, Fagerlund B, Pagsberg AK, Christensen AMR, Nordentoft M, Mortensen EL (2010) Deficient maturation of aspects of attention and executive functions in early onset schizophrenia. *Eur Child Adolesc Psychiatry* 19(10):773–786
15. Teigset CM, Mohn C, Brunborg C, Juuhl-Langseth M, Holmén A, Rund BR (2018) Do clinical characteristics predict the cognitive course in early-onset schizophrenia-spectrum disorders? *J Child Psychol Psychiatry* 59(9):1012–1023. <https://doi.org/10.1111/jcpp.12896>
16. Øie M, Sundet K, Rund BR (2008) Neurocognitive decline in early-onset schizophrenia compared with ADHD and normal controls: evidence from a 13-year follow-up study. *Schizophr Bull* 36(3):557–565
17. Hemager N, Plessen KJ, Thorup A, Christiani C, Ellersgaard D, Spang KS, Burton BK, Gregersen M, Søndergaard A, Greve AN, Gantriis DL, Poulsen G, Seidman LJ, Mors O, Nordentoft M, Jepsen JRM (2018) Assessment of neurocognitive functions in 7-year-old children at familial high risk for schizophrenia or bipolar disorder: the danish high risk and resilience study via 7. *JAMA Psychiatry* 75(8):844–852. <https://doi.org/10.1001/jamapsychiatry.2018.1415>
18. Holmen A, Juuhl-Langseth M, Thormodsen R, Melle I, Rund BR (2010) Neuropsychological profile in early-onset schizophrenia-spectrum disorders: measured with the MATRICS battery. *Schizophr Bull* 36(4):852–859. <https://doi.org/10.1093/schbul/sbn174>
19. Øie M, Sundet K, Ueland T (2011) Neurocognition and functional outcome in early-onset schizophrenia and attention-deficit/hyperactivity disorder: a 13-year follow-up. *Neuropsychology* 25(1):25
20. Rajji T, Ismail Z, Mulsant B (2009) Age at onset and cognition in schizophrenia: meta-analysis. *Br J Psychiatry* 195(4):286–293
21. Frangou S (2013) Neurocognition in early-onset schizophrenia. *Child Adolesc Psychiatr Clin* 22(4):715–726
22. Bombin I, Mayoral M, Castro-Fornieles J, Gonzalez-Pinto A, de la Serna E, Rapado-Castro M, Barbeito S, Parellada M, Baeza I, Graell M, Payá B, Arango C (2013) Neuropsychological evidence for abnormal neurodevelopment associated with early-onset psychoses. *Psychol Med* 43(4):757–768. <https://doi.org/10.1017/S0033291712001535>
23. Maziade M, Gingras N, Rodrigue C, Bouchard S, Cardinal A, Gauthier B, Tremblay G, Cote S, Fournier C, Boutin P, Hamel M, Roy MA, Martinez M, Merette C (1996) Long-term stability of diagnosis and symptom dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence. I: nosology, sex and age of onset. *Br J Psychiatry* 169(3):361–370
24. Gillberg IC, Hellgren L, Gillberg C (1993) Psychotic disorders diagnosed in adolescence. Outcome at age 30 years. *J Child Psychol Psychiatry* 34(7):1173–1185
25. Fleischhaker C, Schulz E, Tepper K, Martin M, Hennighausen K, Remschmidt H (2005) Long-term course of adolescent schizophrenia. *Schizophr Bull* 31(3):769–780. <https://doi.org/10.1093/schbul/sbi014>
26. Lay B, Blanz B, Hartmann M, Schmidt MH (2000) The psychosocial outcome of adolescent-onset schizophrenia: a 12-year followup. *Schizophr Bull* 26(4):801–816
27. Röpcke B, Eggers C (2005) Early-onset schizophrenia. *Eur Child Adolesc Psychiatry* 14(6):341–350
28. Remschmidt H, Martin M, Fleischhaker C, Theisen FM, Hennighausen K, Gutenbrunner C, Schulz E (2007) Forty-two-years later: the outcome of childhood-onset schizophrenia. *J Neural Transm* 114(4):505–512. <https://doi.org/10.1007/s00702-006-0553-z>
29. Cervellione KL, Burdick KE, Cottone JG, Rhinewine JP, Kumra S (2007) Neurocognitive deficits in adolescents with schizophrenia: longitudinal stability and predictive utility for short-term functional outcome. *J Am Acad Child Adolesc Psychiatry* 46(7):867–878. <https://doi.org/10.1097/chi.0b013e318054678d>
30. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull* 13(2):261–276. <https://doi.org/10.1093/schbul/13.2.261>
31. Wallwork R, Fortgang R, Hashimoto R, Weinberger D, Dickinson D (2012) Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. *Schizophr Res* 137(1–3):246–250
32. Langeveld J, Andreassen OA, Auestad B, Færden A, Hauge LJ, Joa I, Johannessen JO, Melle I, Rund BR, Røssberg JI (2013) Is there an optimal factor structure of the Positive and Negative Syndrome Scale in patients with first-episode psychosis? *Scand J Psychol* 54(2):160–165
33. Liddle PF (1987) Schizophrenic syndromes, cognitive performance and neurological dysfunction. *Psychol Med* 17(1):49–57
34. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK (1985) Symptomatic and neuropsychological components of defect states. *Schizophr Bull* 11(3):409–419
35. Dominguez MdG, Viechtbauer W, Simons CJ, van Os J, Krabbendam L (2009) Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. *Psychol Bull* 135(1):157
36. Díaz-Caneja CM, Pina-Camacho L, Rodríguez-Quiroga A, Fraguas D, Parellada M, Arango C (2015) Predictors of outcome in early-onset psychosis: a systematic review. *npj Schizophr* 1:14005
37. Rabinowitz J, Levine SZ, Garibaldi G, Bugariski-Kirola D, Berardo CG, Kapur S (2012) Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. *Schizophr Res* 137(1):147–150. <https://doi.org/10.1016/j.schres.2012.01.015>
38. Smith TE, Hull JW, Huppert JD, Silverstein SM (2002) Recovery from psychosis in schizophrenia and schizoaffective disorder: symptoms and neurocognitive rate-limiters for the development of social behavior skills. *Schizophr Res* 55(3):229–237
39. Ventura J, Helleman GS, Thames AD, Koellner V, Nuechterlein KH (2009) Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. *Schizophr Res* 113(2–3):189–199
40. Lee EHM, Hui CLM, Chan KPK, Chan PY, Law EYL, Chong CSY, Chang WC, Chan SKW, Lee WK, Lo AWF, Pang EPF, Cheung EFC, Yiu MGC, Chung DWS, Ng RMK, Yeung WS, Lo WTL, Chen EYH (2018) The role of symptoms and insight in mediating cognition and functioning in first episode psychosis. *Schizophr Res*. <https://doi.org/10.1016/j.schres.2018.11.009>
41. Wedervang-Resell K, Friis S, Lonning V, Smelror RE, Johannessen C, Reponen EJ, Lyngstad SH, Lekva T, Aukrust P, Ueland T, Andreassen OA, Agartz I, Myhre AM (2019) Increased interleukin 18 activity in adolescents with early-onset psychosis is associated with cortisol and depressive symptoms. *Psychoneuroendocrinology*. <https://doi.org/10.1016/j.psyneuen.2019.104513>
42. Juuhl-Langseth M, Holmén A, Thormodsen R, Øie M, Rund BR (2014) Relative stability of neurocognitive deficits in early onset schizophrenia spectrum patients. *Schizophr Res* 156(2–3):241–247
43. Kaufman J, Birmaher B, Brent D, Rao UMA, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 36(7):980–988. <https://doi.org/10.1097/00004583-199707000-00021>
44. First MB, Spitzer RL, Gibbon M, Williams JB (2002) Structured clinical interview for DSM-IV-TR axis I disorders, research

- version. Biometrics Research, New York State Psychiatric Institute, New York, NY
45. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983) A children's global assessment scale (CGAS). *Arch Gen Psychiatry* 40(11):1228–1231. <https://doi.org/10.1001/archpsyc.1983.01790100074010>
 46. Pedersen G, Hagtvet KA, Karterud S (2007) Generalizability studies of the Global Assessment of Functioning-Split version. *Compr Psychiatry* 48(1):88–94
 47. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th ed., text rev edn. American Psychiatric Association, Washington
 48. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976) The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. *Arch Gen Psychiatry* 33(6):766–771
 49. Fett A-KJ, Viechtbauer W, Penn DL, van Os J, Krabbendam L (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. *Neurosci Biobehav Rev* 35(3):573–588
 50. Schorre BEH, Vandvik IH (2004) Global assessment of psychosocial functioning in child and adolescent psychiatry. *Eur Child Adolesc Psychiatry* 13(5):273–286
 51. Wechsler D (2007) Wechsler abbreviated scale of intelligence (WASI), Norwegian Manual Supplement (trans. B. Ørbeck, K. Sundet). Harcourt Assessment Inc., Stockholm
 52. Nuechterlein KH, Green MF (2009) MATRICS consensus cognitive battery, Norwegian Version (trans. BR Rund, KS Sundet). MATRICS Assessment Inc, Los Angeles, CA
 53. Mayer JD, Salovey P, Caruso D (2002) Mayer–Salovey–Caruso Emotional Intelligence Test (MSCEIT© V2.0). Multi-Health Systems, Toronto
 54. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR (2008) The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. *Am J Psychiatry* 165(2):203–213. <https://doi.org/10.1176/appi.ajp.2007.07010042>
 55. Kelleher I, Clarke MC, Rawdon C, Murphy J, Cannon M (2013) Neurocognition in the extended psychosis phenotype: performance of a community sample of adolescents with psychotic symptoms on the MATRICS neurocognitive battery. *Schizophr Bull* 39(5):1018–1026. <https://doi.org/10.1093/schbul/sbs086>
 56. Smelror RE, Jørgensen KN, Lonning V, Kelleher I, Cannon M, DeRosse P, Malhotra AK, Karlsgodt KH, Andreassen OA, Lundberg M, Edbom T, Cleland N, Ueland T, Myhre AM, Rund BR, Agartz I (2019) Healthy adolescent performance with standardized scoring tables for the MATRICS consensus cognitive battery: a multisite study. *Schizophr Bull* 45(4):773–783. <https://doi.org/10.1093/schbul/sby131>
 57. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L (2004) The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. *Schizophr Res* 68(2):283–297. <https://doi.org/10.1016/j.schres.2003.09.011>
 58. Army Individual Test Battery (1944) Manual of directions and scoring. War Department, Washington, DC
 59. Spreen O, Strauss E (1998) A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, 2nd edn. Oxford University Press, New York
 60. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L (1988) The continuous performance test, identical pairs version (CPT-IP): I. new findings about sustained attention in normal families. *Psychiatry Res* 26(2):223–238. [https://doi.org/10.1016/0165-1781\(88\)90076-5](https://doi.org/10.1016/0165-1781(88)90076-5)
 61. Wechsler D (1997) WMS-III: wechsler memory scale administration and scoring manual. The Psychological Corporation, London
 62. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR (1997) Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. *Arch Gen Psychiatry* 54(2):159–165
 63. Brandt J, Benedict RHB (2001) Hopkins verbal learning test-revised: professional manual. Psychological Assessment Resources, Lutz
 64. Benedict RHB (1997) Brief visuospatial memory test—revised. Psychological Assessment Resources, Odessa
 65. Stern RA, White T (2003) Neuropsychological assessment battery (NAB). Psychological Assessment Resources, Lutz
 66. Stone WS, Mesholam-Gately RI, Giuliano AJ, Woodberry KA, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, McCarley RW, Heinssen R, Green MF, Nuechterlein K, Seidman LJ (2016) Healthy adolescent performance on the MATRICS consensus cognitive battery (MCCB): developmental data from two samples of volunteers. *Schizophr Res* 172(1):106–113. <https://doi.org/10.1016/j.schres.2016.02.003>
 67. Baillargeon A, Lassonde M, Leclerc S, Ellemberg D (2012) Neuropsychological and neurophysiological assessment of sport concussion in children, adolescents and adults. *Brain Inj* 26(3):211–220. <https://doi.org/10.3109/02699052.2012.654590>
 68. Nagle AM, Everhart DE, Durham TW, McCammon SL, Walker M (2006) Deception strategies in children: examination of forced choice recognition and verbal learning and memory techniques. *Arch Clin Neuropsychol* 21(8):777–785
 69. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR (2008) The MATRICS consensus cognitive battery, part 2: co-norming and standardization. *Am J Psychiatry* 165(2):214–220. <https://doi.org/10.1176/appi.ajp.2007.07010043>
 70. August SM, Kiwanuka JN, McMahon RP, Gold JM (2012) The MATRICS consensus cognitive battery (MCCB): clinical and cognitive correlates. *Schizophr Res* 134(1):76–82. <https://doi.org/10.1016/j.schres.2011.10.015>
 71. Mohn C, Sundet K, Rund BR (2014) The relationship between IQ and performance on the MATRICS consensus cognitive battery. *Schizophr Res* 1(2):96–100. <https://doi.org/10.1016/j.scog.2014.06.003>
 72. Preacher KJ, Hayes AF (2008) Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. *Behav Res Methods* 40(3):879–891
 73. Hayes AF (2009) Beyond Baron and Kenny: statistical mediation analysis in the new millennium. *Commun Monogr* 76(4):408–420
 74. Hayes AF, Scharkow M (2013) The relative trustworthiness of inferential tests of the indirect effect in statistical mediation analysis: does method really matter? *Psychol Sci* 24(10):1918–1927
 75. Tuulio-Henriksson A, Partonen T, Suvisaari J, Haukka J, Lönnqvist J (2004) Age at onset and cognitive functioning in schizophrenia. *Br J Psychiatry* 185(3):215–219
 76. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz R-D, Vita A, McGuire P, Borgwardt S (2012) Cognitive functioning in prodromal psychosis: A meta-analysis. *Arch Gen Psychiatry* 69(6):562–571. <https://doi.org/10.1001/archgenpsychiatry.2011.1592>
 77. Hart M, Lewine RR (2017) Rethinking thought disorder. *Schizophr Bull* 43(3):514–522. <https://doi.org/10.1093/schbul/sbx003>
 78. Andreasen NC (1985) Positive vs. negative schizophrenia: a critical evaluation. *Schizophr Bull* 11(3):380–389
 79. Carpenter WT Jr, Heinrichs DW, Wagman AMI (1988) Deficit and nondeficit forms of schizophrenia: the concept. *Am J Psychiatry* 145(5):578

80. Myin-Germeys I, van Os J (2007) Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. *Clin Psychol Rev* 27(4):409–424. <https://doi.org/10.1016/j.cpr.2006.09.005>
81. Brown M, Kuperberg GR (2015) A hierarchical generative framework of language processing: linking language perception, interpretation, and production abnormalities in schizophrenia. *Front Hum Neurosci* 9:643
82. Holshausen K, Bowie CR, Mausbach BT, Patterson TL, Harvey PD (2014) Neurocognition, functional capacity, and functional outcomes: the cost of inexperience. *Schizophr Res* 152(2–3):430–434
83. Moritz S, Klein J, Desler T, Lill H, Gallinat J, Schneider B (2017) Neurocognitive deficits in schizophrenia. Are we making mountains out of molehills? *Psychol Med* 47(15):2602–2612